Status:
UNKNOWN
Pituitary Adenoma and Serum Lipid
Lead Sponsor:
Shandong Provincial Hospital
Conditions:
Pituitary Adenoma 1, Acth-Secreting
Eligibility:
All Genders
Brief Summary
Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu. Thus, it can cause serious he...
Eligibility Criteria
Inclusion
- Patients diagnosed with pituitary adenomas
- All adenomas were resected by transsphenoidal surgery and identified by histological diagnoses.
Exclusion
- Missing vital data, such as age, gender, serum lipid profile, pathology reports;
- Complications or conditions that affect pituitary status and lipid metabolism, such as pregnancy, malignant adenomas or severe hepatic or renal dysfunction and
- Use of any medication that affects the pituitary or lipid metabolism, including statins, fibrates, thyroid hormones, anti-thyroid drugs, iodine, amiodarone, alemtuzumab, lithium, tyrosine kinase inhibitors, interferon, estrogens, androgens,glucocorticoids, nonsteroidal anti-inflammatory drugs, antiepileptic drugs, rifampicin, furosemide, heparin or β-adrenoceptor blockers in the past 3 months.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04021212
Start Date
September 1 2020
End Date
June 1 2024
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Provincial Hospital
Jinan, Shandong, China, 250021